Assessment of adverse effects of neurotropic drugs in monkeys with the "Drug Effects on the Nervous System" (DENS) scale

Journal of Neuroscience Methods

Volumn 215, Issue 1, 2013, Pages 97-102

  Uthayathas, Subramaniam ^a   Shaffer, Christopher L ^b   Menniti, Frank S ^c   Schmidt, Christopher J ^b   Papa, Stella M ^a,d  

^a EMORY UNIVERSITY   (United States)

^b PFIZER INC   (United States)

^c Mnemosyne Pharmaceuticals Inc   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Neurotropics; Normal monkeys; Rating scale; Receptor occupancy; Side effects

Indexed keywords

NEUROTROPIC AGENT; PALIPERIDONE; RISPERIDONE; SEROTONIN 2A RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ASSESSMENT; COGNITION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFECT ON THE NERVOUS SYSTEM SCALE; DRUG RESPONSE; HAPLORHINI; INTERRATER RELIABILITY; NONHUMAN; PRIORITY JOURNAL; RATING SCALE; SENSORIMOTOR FUNCTION; STANDARD MOTOR DISABILITY SCALE;

ALGORITHMS; ANIMALS; ANTIPSYCHOTIC AGENTS; AUTONOMIC NERVOUS SYSTEM; BASAL GANGLIA DISEASES; BEHAVIOR, ANIMAL; CEREBRAL CORTEX; DYSKINESIA, DRUG-INDUCED; FEMALE; MACACA FASCICULARIS; MACACA MULATTA; MALE; NERVOUS SYSTEM; OBSERVER VARIATION; PSYCHOTROPIC DRUGS; RECEPTORS, DRUG; REFERENCE STANDARDS; RISPERIDONE;

EID: 84875791040     PISSN: 01650270     EISSN: 1872678X     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2013.02.004     Document Type: Article

References (24)

1. Casey D.E. Behavioral effects of sertindole, risperidone, clozapine and haloperidol in Cebus monkeys. Psychopharmacology (Berl) 1996, 124:134-140.
2. Casey D.E. Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman-primates. Psychopharmacology (Berl) 1993, 112:S55-S59.
3. Day J.C., Wood G., Dewey M., Bentall R.P. A self-rating scale for measuring neuroleptic side-effects-validation in a group of schizophrenic-patients. Br J Psychiatry 1995, 166:650-653.
4. De Deyn P.P., Rabheru K., Rasmussen A., Bocksberger J.P., Dautzenberg P.L.J., Eriksson S., et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999, 53:946-955.
5. Doran A.C., Osgood S.M., Mancuso J.Y., Shaffer C.L. An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations. Drug Metab Dispos 2012, 40:2162-2173.
6. Fibiger H.C. Psychiatry, the pharmaceutical industry, and the road to better therapeutics. Schizophr Bull 2012, 38:649-650.
7. Folstein M.F., Folstein S.E., McHugh P.R. " Mini-mental state" A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12:189-198.
8. Gwet K.L. Computing inter-rater reliability and its variance in the presence of high agreement. Br J Math Stat Psychol 2008, 61:29-48.
9. Hyman S.E. Revolution stalled. Sci Transl Med 2012, 4. 1555cm cm11.
10. ILAR Guide for the care and use of laboratory animals. Institute of Laboratory Animal Resources-Commission on Life Sciences NRC, editor 1996.
11. Koch H.J., Gurtler K., Szecsey A. Correlation of Mini-Mental-State-Examination (MMSE), Syndrom-Kurztest (SKT) and Clock test (CT) scores in patients with cognitive impairment assessed by means of multiple regression and response surface analysis. Arch Gerontol Geriatr 2005, 40:7-14.
12. Kola I., Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat Rev Drug Discov 2004, 3:711-715.
13. Kumar R., Palit G., Dhawan B.N. Comparative behavioural effects of typical and atypical antipsychotic drugs in rhesus monkey. Eur J Pharmacol 2003, 462:133-138.
14. Landolt H.P., Wehrle R. Antagonism of serotonergic 5-HT2A/2C receptors: mutual improvement of sleep, cognition and mood?. Eur J Neurosci 2009, 29:1795-1809.
15. Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., Elgen K. The Uku side-effect rating-scale-a new comprehensive rating-scale for psychotropic-drugs and a cross-sectional study of side-effects in neuroleptic-treated patients-preface. Acta Psychiatr Scand 1987, 76:7.
16. Mukherjee J., Christian B.T., Narayanan T.K., Shi B., Mantil J. Evaluation of dopamine D-2 receptor occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain using 18F-fallypride. Neuropsychopharmacology 2001, 25:476-488.
17. Nyberg S., Eriksson B., Oxenstierna G., Halldin C., Farde L. Suggested minimal effective dose of risperidone based on PET-measured D-2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry 1999, 156:869-875.
18. Papa S.M., Auberson Y.P., Greenamyre J.T. Prolongation of levodopa responses by glycine(B) antagonists in parkinsonian primates. Ann Neurol 2004, 56:723-727.
19. Papa S.M., Chase T.N. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann Neurol 1996, 39:574-578.
20. Schotte A., Janssen P.F.M., Gommeren W., Luyten W.H.M.L., VanGompel P., Lesage A.S., et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996, 124:57-73.
21. Shaffer C.L. Defining neuropharmacokinetic parameters in CNS drug discovery to determine cross-species pharmacologic exposure-response relationships. Annu Rep Med Chem 2010, 45:55-70.
22. Stip E. Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics. J Psychiatry Neurosci 2000, 25:137-153.
23. Terry A.V., Buccafusco J.J., Bartoszyk G.D. Selective serotonin 5-HT2A receptor antagonist EMD 281014 improves delayed matching performance in young and aged rhesus monkeys. Psychopharmacology (Berl) 2005, 179:725-732.
24. Venkatakrishnan K., Tseng E., Nelson F.R., Rollema H., French J.L., Kaplan I.V., et al. Central nervous system pharmacokinetics of the mdr1 p-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures. Drug Metab Dispos 2007, 35:1341-1349.